A federal panel of judges has decided to consolidate testosterone lawsuit claims over AndroGel and similar hormone treatment therapies in the U.S. District Court, Northern District of Illinois, where “a significant number” of cases have already been filed, Bloomberg.com reports.

According to a decision on June 6, 2014, the newly-established multidistrict litigation will involve medications that may be tied to serious and life-threatening cardiovascular injuries. Many of the testosterone lawsuits now filed in the proceeding similarly blame Abbott Laboratories (ABT) and AbbVie Inc. for injuries allegedly caused by AndroGel, which is just one “Low T” testosterone drug that has reportedly been under federal investigation for the past several months. In a public health alert issued by the U.S. Food and Drug Administration (FDA) on January 31, 2014, the agency vowed to investigate AndroGel, Axiron, and other drugs after two studies associated their use with an increased risk of strokes, heart attacks, and death in all older men and younger men with pre-existing heart problems.

At least 45 testosterone lawsuits will be affected by the U.S. Judicial Panel on Multidistrict Litigation’s Transfer Order, which further states that 81 similar claims over AndroGel and other medications are currently pending in separate federal jurisdictions throughout the U.S. In its June decision, the Panel said it chose to centralize all “Low T” lawsuits since the testosterone drug-related actions in the U.S. involve several products.  Plaintiffs have predicted a steady increase in the number of claims filed in this industry-wide litigation.

Testosterone Lawsuit Defendants Support Creation of Industry-Wide MDL

According to Bloomberg, one of the companies preparing to defend AndroGel lawsuits has already voiced its opinion on the newly-established proceeding. A spokesperson for AbbVie said the North Chicago, Illinois-based company supports the centralization of similar claims over AndroGel “in the interest of consistency and efficiency.”

The report also indicates that Abbott and AbbVie have already been named in patient suits that seek more than $80 million in damages allegedly resulting from the company’s marketing of AndroGel. Plaintiffs allege that a 2012 campaign advertised the medication for use in treating men with low libido, fatigue and other common symptoms of aging. The drug manufacturers referred to this condition as “Low T.”

Other companies preparing to defend testosterone lawsuits include Pfizer Inc. and Actavis Inc., according to Bloomberg.

Contact a Testosterone Lawyer Today

Call our Firm today to learn more about testosterone lawsuits, and whether you may be eligible to file a claim against the makers of AndroGel or another medication. Call us now at (877) 779-1414.

Published June 12, 2014 by